New ATS guidelines. Bye bye spiriva

[anonymous]

Not good news for us when you read new ATS guidelines Strong recommendation to use lama/laba vs lama. Stiolto won’t win. Anoro will

 

[anonymous]

Not good news for us when you read new ATS guidelines Strong recommendation to use lama/laba vs lama. Stiolto won’t win. Anoro will

Aren't they already?

 

[anonymous]

The war is over. BI lost a long time ago.

 

[anonymous]

I’m surprised that we have what we have in market share. We will lose more major formulary coverage within a year.

 

[anonymous]

Really sad to see what Bi has done to its respiratory side. They had the #1 copd drug in the world for years. They could control the market. They decided the Respimat device was the way to go. What a massive failure that was. They didn’t get a triple. Game over. Sad.

 

[anonymous]

Really sad to see what Bi has done to its respiratory side. They had the #1 copd drug in the world for years. They could control the market. They decided the Respimat device was the way to go. What a massive failure that was. They didn’t get a triple. Game over. Sad.

Yet if I had COPD I would want Respimat ...I see how my relatives love it.

 

[anonymous]

Not good news for us when you read new ATS guidelines Strong recommendation to use lama/laba vs lama. Stiolto won’t win. Anoro will

Yawn...old news. This has been out even before the pandemic hit. Try again.

 

[anonymous]

Really sad to see what Bi has done to its respiratory side. They had the #1 copd drug in the world for years. They could control the market. They decided the Respimat device was the way to go. What a massive failure that was. They didn’t get a triple. Game over. Sad.

If Pfizer wasn't there to hold our hand, we would have never had the #1 COPD drug in the world.

 

[anonymous]

If Pfizer wasn't there to hold our hand, we would have never had the #1 COPD drug in the world.

they're a HUGE power house with formulary status..that's what it takes.

 

[anonymous]

Rest in Mist
Behold the formulary major league prowess of GSK / AZ
Bush League BI had some good seasons when the only competition was a nebulizer
Mist is certainly novel just not practical financially to justify minimal efficacy advantages
Saw one of those awesome video players in a stack of garage the other day ahh fond memories

 

[anonymous]

they're a HUGE power house with formulary status..that's what it takes.

pfizer had/has nothing to do with Spiriva formulary access. BI owned the molecule and subsequently, BI was/is responsible for the managed care access

Pfizer is NOT a formulary powerhouse. You’re mistaken.

 

[anonymous]

Rest in Mist
Behold the formulary major league prowess of GSK / AZ
Bush League BI had some good seasons when the only competition was a nebulizer
Mist is certainly novel just not practical financially to justify minimal efficacy advantages
Saw one of those awesome video players in a stack of garage the other day ahh fond memories

Your opinion has already been disproven by real world evidence. Try again.

 

[anonymous]

pfizer had/has nothing to do with Spiriva formulary access. BI owned the molecule and subsequently, BI was/is responsible for the managed care access

Pfizer is NOT a formulary powerhouse. You’re mistaken.

au contraire but they ARE and I'm sure "their voice" helped our cause..

 

[anonymous]

Your opinion has already been disproven by real world evidence. Try again.

Which American Journal was that published in again?

 

[anonymous]

Which American Journal was that published in again?

It’s published in the American Journal of Real World Medical Practice - you know, the one that actually is reflective and most accurate of the point-of-care reality of treating patients.

 

[anonymous]

It’s published in the American Journal of Real World Medical Practice - you know, the one that actually is reflective and most accurate of the point-of-care reality of treating patients.

right...still trying to find a reputable publication to take your cause.

 

[anonymous]

pfizer had/has nothing to do with Spiriva formulary access. BI owned the molecule and subsequently, BI was/is responsible for the managed care access

Pfizer is NOT a formulary powerhouse. You’re mistaken.

Wrong! Pfizer had the connections in the hospitals and health systems to get Spiriva on formularies. Those of us still here can remember back in 2004 watching Pfizer in awe. BI may have owned the molecule, but only a fool wouldn't credit Pfizer with the foundational success of Spiriva. Did you ever wonder how Stiolto would have done if Pfizer would have been around for that launch?

 

[anonymous]

Let’s put it this way. Pfizer helped us slightly less for Spiriva than Lilly does for Jardiance.

considering Lily does little to help us, that should tell you where Pfizer ranks.

the ONLY reason they had any interest in Spiriva was because they were trying to leverage it to help the Chantix cause.

 

[anonymous]

right...still trying to find a reputable publication to take your cause.

is Penthouse Forum still in circulation?